Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Petitioning FDA Is "Hard" But "Right Way" To Sell Former IND As Supplement

This article was originally published in The Tan Sheet

Executive Summary

A recent citizen petition blazes a trail for companies to market ingredients for supplements that would otherwise be regulated as drugs after previously undergoing investigation as a drug
Advertisement

Related Content

Novartis Extends Triaminic Into Brand Name Void Left By J&J Tylenol Recall
Novartis Extends Triaminic Into Brand Name Void Left By J&J Tylenol Recall
Novartis Extends Triaminic Into Brand Name Void Left By J&J Tylenol Recall
Bioenergy Rides Pharma Science Down Rx, Supplement Roads
Bioenergy Rides Pharma Science Down Rx, Supplement Roads
Ovos Plots Vivimind Cognitive Supplement Launch, Awaits FDA Reply
FDA Must Lift "Limbo" Over Trials In Supplement Development - Caucus
Brain Gain: Supplements And Nutraceuticals Expand Cognitive Health Science
Senate Puts FDA On Notice To Solve FDAAA Sec. 912 Puzzle
Senate Puts FDA On Notice To Solve FDAAA Sec. 912 Puzzle

Topics

Advertisement
UsernamePublicRestriction

Register

PS103163

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel